Ridinger M H T
Clin Pharmacol Ther. 2007 May;81(5):624-6. doi: 10.1038/sj.clpt.6100196.
Welfare recipients in the United States are three times as likely to suffer from depression and anxiety as average Americans. Although affordable pharmacotherapy options are readily available in more affluent parts of society, welfare programs are ineffective in facilitating diagnosis and therapy that could help the affected improve their lives and even ultimately become gainfully employed and off taxpayer-supported welfare programs. To the benefit of all, more "bang for the buck" is within reach with common pharmacotherapy, but the question remains: who will wake up and champion the obvious?
美国的福利领取者患抑郁症和焦虑症的可能性是普通美国人的三倍。尽管在社会较为富裕的地区，价格亲民的药物治疗方案随处可得，但福利项目在促进诊断和治疗方面却毫无成效，而这些诊断和治疗本可帮助患者改善生活，甚至最终实现有收益的就业并摆脱纳税人资助的福利项目。对所有人来说，常见的药物治疗能带来更大的益处，但问题依然存在：谁会醒悟过来并支持这一显而易见的做法呢？
